Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Phase 1

Completed

• Conditions: Glioma
• Interventions: Drug: AG-120; Drug: AG881

• Registration Number: NCT03343197
• Lead Sponsor: Institut de Recherches Internationales Servier

Brief Summary

Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.

Detailed Description

A phase-1, multi-center study in recurrent non-enhancing gliomas with IDH1 R132H mutation for patients who require surgery. The purpose of this study is to evaluate the suppression of 2-HG by comparing the concentration of 2-HG in resected tumors from IDH1 mutant glioma subjects following AG-120 or AG-881 treatment with the 2-HG concentration in untreated, control tumors. The safety, tolerability, PK/PD, and anti tumor activity data from the study in subjects with recurrent non-enhancing Grade 2/3 LGG with an IDH1 R132H mutation for whom surgical resection is indicated will identify the recommended dose of AG-120 and AG-881 for future studies in glioma.

Study Timeline

• Study First Submitted: 2017-11-07
• Study First Submitted QC: 2017-11-09
• Study First Posted: 2017-11-17
• Study Start: 2018-03-20
• Primary Completion: 2019-08-02
• Study Completion: 2025-03-28
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-14
• Last Update Posted: 2025-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 49

Inclusion Criteria

1. Be ≥18 years of age.
2. Have histologically or cytologically confirmed recurrent Grade 2 or 3 LGG (oligodendroglioma or astrocytoma according to World Health Organization 2016 classification).
3. Have documented IDH1 R132H gene mutation by local testing and known 1p19q or ATRX mutation status by local testing.
4. Have central confirmation of primarily non-enhancing disease by MRI with less than or equal to 5 mm slice thickness and up to 1 mm interslice gap on either 2D T2 weighted image, 3D T2 weighted image, or FLAIR, with at least 1 non-enhancing tumor measuring 1×1×1 cm.
5. Be candidates for clinical resection but for whom surgery is not urgently indicated (eg, for whom surgery within the next 2-4 months is appropriate).
6. Have KPS of ≥60%
7. Have expected survival of ≥12 months.

Exclusion Criteria

1. Have received prior systemic anti-cancer therapy within 1 month of the first dose of AG-120 or AG-881 or have received an investigational agent <14 days prior to their first dose of AG-120 or AG-881. In addition, the first dose of AG-120 or AG-881 should not occur before a period of ≥5 half-lives of the investigational agent has elapsed.
2. Have had radiation within 6 months of the first dose of AG-120 or AG-881. (Note: Prior biopsy or surgery is allowed.)
3. Have received any prior treatment with an IDH inhibitor.
4. Have received any prior treatment with bevacizumab (Avastin).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AG-120	AG-120	AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-120 .
AG-881	AG881	AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle prior to surgery. Following surgery, subjects will have the option to receive treatment with AG-881.

Primary Outcome Measures

Name	Time	Method
2-HG concentration in surgically resected tumors	Up to 4 weeks, on average

Secondary Outcome Measures

Name	Time	Method
Safety and tolerability: incidence of adverse events and serious adverse events	Up to 48 weeks, on average
Pharmacodynamics of AG-120 or AG-881 measured by 2-HG concentration in plasma.	Up to 4 weeks, on average
Peak Plasma Concentration (Cmax) of AG-120 or AG-881	Up to 4 weeks, on average
Time to maximum concentration (Tmax) of AG-120 or AG-881	Up to 4 weeks, on average
Area Under the Curve (AUC) of AG-120 or AG-881	Up to 4 weeks, on average
Elimination half-life of AG-120 or AG-881	Up to 4 weeks, on average
Clinical activity associated with AG-120 or AG-881 according to modified RANO_LGG criteria.	Up to 48 weeks, on average

Trial Locations

Locations (5)

United States, New York; 🇺🇸 New York, New York, United States

United States, California; 🇺🇸 San Francisco, California, United States

United States, Massachusetts; 🇺🇸 Boston, Massachusetts, United States

United States, North Carolina; 🇺🇸 Durham, North Carolina, United States

United States, Texas; 🇺🇸 Dallas, Texas, United States